---
layout: default
title: Sevoflurane
parent: Model Prediction Only (L5)
nav_order: 1158
evidence_level: L5
indication_count: 10
---

# Sevoflurane
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sevoflurane: From General Anesthesia to Prinzmetal Angina

## One-Sentence Summary

Sevoflurane is an inhaled volatile agent marketed in the United States for general anesthesia.
The TxGNN model predicts it may be effective for **Prinzmetal angina**, but this rests on the model score alone, with **0 clinical trials** and **0 publications** supporting this specific indication.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Prinzmetal angina |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 14 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for sevoflurane. Based on general pharmacology, volatile anesthetics relax vascular smooth muscle and modulate calcium handling. Prinzmetal angina is caused by coronary vasospasm, so vasodilation could plausibly counter it.

This link is speculative. Sevoflurane is a short-term general anesthetic, not a chronic anti-anginal, and no supporting data were provided. A high graph-based score by itself is not evidence of clinical benefit. Any relevance would probably be limited to perioperative or acute settings, and the route (inhalation) is a major practical constraint.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|------|
| ANDA214382 | Sevoflurane | Liquid | Lannett Company, Inc. |
| ANDA077867 | Sojourn | Liquid | Piramal Critical Care Inc |
| ANDA214382 | Sevoflurane (Volatile for Inhalation) | Liquid | Mullan Pharmaceutical Inc. |
| ANDA203793 | Sevoflurane | Liquid | Sandoz Inc. |
| ANDA214382 | Sevoflurane | Liquid | Shandong New Time Pharmaceutical Co., Ltd. |

---

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found in the queried data.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Prinzmetal angina prediction has a very high model score but no trials or publications behind it. The proposed mechanism is generic and speculative, and sevoflurane's short-term inhaled use does not fit chronic angina management. The evidence does not justify moving forward.

Other top-ranked predictions are also weak. Fibromyalgia, tendinitis and inclusion body myositis are supported only by anesthetic-management case reports or surgical-setting studies. The single migraine trial studies postoperative headache as an adverse outcome, which may point the opposite way.

**To proceed, the following is needed:**
- Mechanism of action data (MOA) from DrugBank
- Package insert warnings and contraindications, needed for safety screening
- Preclinical or clinical data on sevoflurane in coronary vasospasm (for example, animal models or perioperative studies in vasospastic angina patients)
- An assessment of whether an inhaled anesthetic route is compatible with the intended use
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

